Compare · HSDT vs NXL
HSDT vs NXL
Side-by-side comparison of Solana Company (HSDT) and Nexalin Technology Inc. (NXL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HSDT and NXL operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- HSDT is the larger of the two at $108.8M, about 59.4x NXL ($1.8M).
- NXL has been more active in the news (5 items in the past 4 weeks vs 4 for HSDT).
- HSDT has more recent analyst coverage (3 ratings vs 0 for NXL).
- Company
- Solana Company
- Nexalin Technology Inc.
- Price
- -
- -
- Market cap
- $108.8M
- $1.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 4
- 5
- Recent ratings
- 3
- 0
Solana Company
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Latest HSDT
- SEC Form 10-Q filed by Solana Company
- Solana Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Solana Company Reports Third Quarter 2026 Financial Results
- Solana Company to Release Third Quarter 2026 Operating Results on November 11, 2026
- Solana Company Selected as a Strategic Enterprise by the Hong Kong SAR Government
- SEC Form 424B5 filed by Solana Company
- Solana Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Solana Company (NASDAQ: HSDT) Announces Pricing of $15 Million Registered Direct Offering with a Global Institutional Investor
- SEC Form 4 filed by Officer Tjandrasuwita Agustina Gani
- Solana Company Announces Positions and Votes on first Solana Governance Proposals
Latest NXL
- Amendment: SEC Form SCHEDULE 13D/A filed by Nexalin Technology Inc.
- SEC Form 10-Q filed by Nexalin Technology Inc.
- SEC Form DEF 14A filed by Nexalin Technology Inc.
- Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease
- SEC Form PRE 14A filed by Nexalin Technology Inc.
- SEC Form EFFECT filed by Nexalin Technology Inc.
- Amendment: SEC Form S-1/A filed by Nexalin Technology Inc.
- Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
- Nexalin Technology Inc. filed SEC Form 8-K: Other Events
- Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits